Recent Quotes (30 days)

You have no recent quotes
chg | %

Regeneus Ltd  

(Public, ASX:RGS)   Watch this stock  
Find more results for RGS
-0.005 (-4.00%)
Feb 20 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.12 - 0.12
52 week 0.10 - 0.16
Open 0.12
Vol / Avg. 21,871.00/179,834.00
Mkt cap 25.07M
P/E 8.06
Div/yield     -
EPS 0.01
Shares 208.89M
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '17) 2017
Net profit margin -25.90% 32.48%
Operating margin -25.90% 32.52%
EBITD margin - 39.57%
Return on average assets -9.95% 43.32%
Return on average equity -11.64% 50.77%
CDP Score - -


Ground floor, 25 Bridge St
+61-2-94998010 (Phone)
+61-2-94998020 (Fax)

Website links


Regeneus Ltd is a clinical-stage regenerative medicine company. The Company is engaged in developing cell-based therapies for human and animal health markets, with a focus on osteoarthritis and musculoskeletal disorders, as well as oncology and dermatology diseases. The Company's portfolio of therapeutic products is being developed using stem cell and immune oncology technology platforms. The Company's technology platform includes approximately three platforms across both human and animal health businesses, including Human and animal adipose-derived mesenchymal stem cells (MSCs) for the treatment of musculoskeletal diseases; Human and animal immunotherapy personalized cancer vaccine for the treatment of various cancers, and Stem cell secretions cell free supernatant (CFS) technology harnessing the therapeutic potential of mesenchymal stem cells for skincare treatments. The Company's products include Kvax, CryoShot, Progenza, Human Cancer Vaccine and Secretions Cream.

Officers and directors

John Dominic Martin Chief Executive Officer, Director
John Bird Chief Financial Officer and Operations Officer
Graham Vesey Chief Scientific Officer, Executive Director
Sandra McIntosh Office/Human Resources Manager, Company Secretary
Charlotte Morgan Head - Laboratory, Research and Development
Duncan Thomson Head - Veterinary Health
Roger Aston Ph.D. Non-Executive Independent Chairman of the Board
Barry G. Sechos Non-Executive Director
Leo Lee Non-Executive Independent Director
Glen Frank Richards Independent Non-Executive Director